GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated September 12, 2024, serves as a transaction notification for the month of September 2024. The document discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It strictly reports on specific equity transactions.
| Transaction Date | Instrument | Price per Share | Total Volume (Shares) | Exchange |
|---|---|---|---|---|
| 2024-09-10 | Ordinary Shares (31 1/2 pence each) | £16.6928 | 126 (Aggregated) | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details routine share acquisitions by senior executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Transaction Type: All reported transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan, consisting of partnership shares and matching shares.
- Participants: Transactions were executed by eight senior executives, including CEO Emma Walmsley, CFO Julie Brown, and Company Secretary Victoria Whyte.
- Volume Details: Most executives acquired 16 shares (8 partnership + 8 matching), while Regis Simard, Philip Thomson, and Deborah Waterhouse acquired 14 shares (7 partnership + 7 matching).
- Valuation: All shares were acquired at a uniform price of £16.6928 per share.
- Scope: This filing does not reflect the company's quarterly or annual financial performance.